{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:42:33Z","timestamp":1770345753725,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113102","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:49:03Z","timestamp":1726220943000},"page":"113102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"PA","title":["Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3084-5747","authenticated-orcid":false,"given":"Xiaomu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianquan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaoyong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-7878","authenticated-orcid":false,"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2024.113102_b0005","doi-asserted-by":"crossref","first-page":"P25","DOI":"10.1164\/rccm.2029P25","article-title":"What is asthma?","volume":"202","author":"Sockrider","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113102_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113102_b0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"2023 GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.113102_b0020","doi-asserted-by":"crossref","first-page":"e20221212","DOI":"10.1084\/jem.20221212","article-title":"Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight","volume":"220","author":"Howell","year":"2023","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.113102_b0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.anai.2019.08.462","article-title":"Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4\/5 therapy in the United States","volume":"123","author":"Settipane","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113102_b0030","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.pt.2017.05.004","article-title":"Th2 and Th1 responses: clear and hidden sides of immunity against intestinal helminths","volume":"33","author":"Cort\u00e9s","year":"2017","journal-title":"Trends Parasitol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113102_b0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.chest.2016.10.042","article-title":"Epithelial-derived cytokines in asthma","volume":"151","author":"Mitchell","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2024.113102_b0040","doi-asserted-by":"crossref","unstructured":"J. Zhong, J. Sharma, R. Raju, et al., TSLP signaling pathway map: a platform for analysis of TSLP-mediated signalling, Database (Oxford). 2014;2014:bau007. Published 2014 Feb 25. doi:10.1093\/database\/bau007.","DOI":"10.1093\/database\/bau007"},{"issue":"2","key":"10.1016\/j.intimp.2024.113102_b0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/02770900903483816","article-title":"Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells","volume":"47","author":"Li","year":"2010","journal-title":"J. Asthma"},{"issue":"10","key":"10.1016\/j.intimp.2024.113102_b0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41577-020-0301-x","article-title":"Heterogeneity in the initiation, development and function of type 2 immunity","volume":"20","author":"Gause","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113102_b0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41423-019-0210-8","article-title":"Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses","volume":"16","author":"Gurram","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113102_b0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12931-016-0321-z","article-title":"IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma","volume":"17","author":"Salter","year":"2016","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.113102_b0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41385-019-0232-7","article-title":"IL-4R\u03b1 expression by airway epithelium and smooth muscle accounts for nearly all airway hyperresponsiveness in murine allergic airway disease","volume":"13","author":"McKnight","year":"2020","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113102_b0070","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2014.12.1918","article-title":"Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma","volume":"135","author":"Smith","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113102_b0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"19","key":"10.1016\/j.intimp.2024.113102_b0080","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113102_b0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.intimp.2024.113102_b0090","doi-asserted-by":"crossref","unstructured":"M. Castro, J. Zangrilli, M.E. Wechsler, et al., Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials [published correction appears in Lancet Respir Med. 2015 Apr;3(4):e15] [published correction appears in Lancet Respir Med. 2016 Oct;4(10):e50].Lancet Respir Med. 2015;3(5):355-366. doi:10.1016\/S2213-2600(15)00042-9.","DOI":"10.1016\/S2213-2600(15)00042-9"},{"issue":"10056","key":"10.1016\/j.intimp.2024.113102_b0095","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2024.113102_b0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9842","key":"10.1016\/j.intimp.2024.113102_b0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.intimp.2024.113102_b0110","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.113102_b0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41385-020-0266-x","article-title":"Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation","volume":"13","author":"Kabata","year":"2020","journal-title":"Mucosal Immunol."},{"issue":"45","key":"10.1016\/j.intimp.2024.113102_b0120","doi-asserted-by":"crossref","first-page":"19455","DOI":"10.1073\/pnas.1008271107","article-title":"Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling","volume":"107","author":"Rochman","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2024.113102_b0125","doi-asserted-by":"crossref","unstructured":"Y. Rochman, K. Dienger-Stambaugh, P.K. Richgels, et al., TSLP signaling in CD4+T cells programs a pathogenic T helper 2 cell state, Sci. Signal 11(521) (2018) eaam8858. Published 2018 Mar 13. doi:10.1126\/scisignal.aam8858.","DOI":"10.1126\/scisignal.aam8858"},{"issue":"7","key":"10.1016\/j.intimp.2024.113102_b0130","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/imcb.12644","article-title":"CCL17\/TARC in autoimmunity and inflammation-not just a T-cell chemokine","volume":"101","author":"Lupancu","year":"2023","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113102_b0135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1165\/rcmb.2020-0011OC","article-title":"Rhinovirus-induced CCL17 and CCL22 in asthma exacerbations and differential regulation by STAT6","volume":"64","author":"Williams","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"#cr-split#-10.1016\/j.intimp.2024.113102_b0140.1","doi-asserted-by":"crossref","unstructured":"V. Soumelis, Y.J. Liu, The discovery of human TSLP as a critical epithelial cytokine in type 2 immunity and allergic disease [published correction appears in Nat Immunol. 2020 Jul 17;:], Nat. Immunol. 21","DOI":"10.1038\/s41590-020-0757-7"},{"key":"#cr-split#-10.1016\/j.intimp.2024.113102_b0140.2","doi-asserted-by":"crossref","unstructured":"(12) (2020) 1471-1473. doi:10.1038\/s41590-020-0720-7.","DOI":"10.1038\/s41590-020-0720-7"},{"key":"10.1016\/j.intimp.2024.113102_b0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaci.2013.05.011","article-title":"Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma","volume":"132","author":"Cheng","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113102_b0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2024.113102_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156091","article-title":"IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline","volume":"162","author":"Scott","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2024.113102_b0160","unstructured":"US Food & Drug Administration. TEZSPIRE\u2122 (tezepelumab-ekko) injection, for subcutaneous use Initial U.S. Approval: 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761224s000lbl.pdf."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924016230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924016230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:54:57Z","timestamp":1728010497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924016230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"alternative-id":["S1567576924016230"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113102","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113102"}}